Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
Increased Tissue Damage and Lesion Volumes in African Americans with Multiple Sclerosis
Neurol 74:538-544,532, Weinstock-Guttman,B.,et al, 2010
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
Brainstem Lesion in Clinically Isolated Syndromes
Neurol 75:1933-1938, Tintore,M.,et al, 2010
Evidence for Acute Neurotoxicity After Chemotherapy
Ann Neurol 68:806-815, Petzold,A.,et al, 2010
Early MRI in Optic Neuritis: The Risk for Disability
Neurol 72:542-550, Swanton,.K.,et al, 2009
Gray Matter Involvement in Multiple Sclerosis
Neurol 68:634-642, Pirko,I.,et al, 2007
Magnetic Resonance Imaging as a Surrogate Outcome Measure of Disability in Multiple Sclerosis: Have We Been Overly Harsh in Our Assessment?
Ann Neurol 59:597-605, Goodin,D.S., 2006
MRI T2 Lesion Burden in Multiple Sclerosis. A Plateauing Relationship with Clinical Disability.
Neurol 66:1384-1389, Li,D.K.B.,et al, 2006
Internuclear Ophthalmoplegia
Arch Neurol 62:714-717, Keane,J.R., 2005
Clinical Characteristics of African Americans vs Caucasian Americans with Multiple Sclerosis
Neurol 63:2039-2045, Bree,B.A.C.,et al, 2004
A Longitudinal Study of Abnormalities on MRI and Disability From Multiple Sclerosis
NEJM 346:158-164,199, Brex,P.A.,et al, 2002
Application of the New McDonald Criteria to Patients with Clinically Isolated Syndromes Suggestive of Mulitple Sclerosis
Ann Neurol 52:47-53, Dalton,C.M.,et al, 2002
Multiple Sclerosis and Magnetic Resonance Imaging
Arch Neurol 58:35-36, Racke,M.K.,et al, 2001
PRISMS-4: Long-Term Efficacy of Interferon-B-1a in Relapsing MS
Neurol 56:1628-1636,1620, The PRISMS Study Group, 2001
Quantitative MRI in Patients with Clinically Isolated Syndromes Suggestive of Demyelination
Neurol 52:599-606, Sailer,M.,et al, 1999
Isolated Cranial Nerve Palsies Due to Brainstem Lesions
Muscle & Nerve 22:1168-1176, Thomke,F., 1999
Serial Neuropsychological Assess & Magnetic Resonance Imagingf Analysis in Multiple Sclerosis
Arch Neurol 54:1018-1025, Hohol,M.J.,et al, 1997
Palliative Care in Neurology
Neurol 46:870-872, 5981996., Bernat,J.L.,et al, 1996
Twelfth-Nerve Palsy:Analysis of 100 Cases
Arch Neurol 53:561-566, Keane,J.R., 1996
Neurologic Aspects of Inflammatory Bowel Disease
Neurol 45:416-421, Lossos,A.,et al, 1995
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
Ocular Torsion and Tilt of Subjective Visual Vertical are Sensitive Brainstem Signs
Ann Neurol 33:292-299, Dieterich,M.&Brandt,T., 1993
Surgical Treatment of Cervical Spondylotic Myelopathy:Time for a Controlled Trial
Neurol 42:5-13, Rowland,L.P., 1992
Divisional Oculomotor Nerve Paresis Caused by Intrinsic Brainstem Disease
Ann Neurol 26:714-718, Ksiazek,S.M.,et al, 1989
Oligoclonal IgG Bands in Cerebrospinal Fluid in Various Neurological Diseases
Ann Neurol 13:434-439, Chu,A.B.,et al, 1983
Occurrence of Oligoclonal Bands in Multiple Sclerosis & Other CNS Diseases
Ann Neurol 13:53-58, Miller,J.R.,et al, 1983
Bilateral Sixth Nerve Palsy
Arch Neurol 33:681, Keane,J.R., 1976
The Geography of Neurology
BMJ 2:506, Spillane,J.D., 1972
Neuro CPC of MGH
Multiple Sclerosis, Cerebral Infarcts, & Colitis, NEJM 268:607-615., , 1963
The Optic Nerve Should Graduate to Be the Fifth Lesion Site for the Diagnosis of Multiple Sclerosis
Neurol 102:e207919, Galetta,S. & Brownlee, W., 2024
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Management of Possible Multiple Sclerosis
NEJM 388:2195-2190, , 2023
Association of Very Early treatment Initiation with the Risk of Long-Term Disability in Patients with a First Demyelinating Event
Neurol 101:e1280-e1292, 549, Cobo-Calvo,A.,et al, 2023
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Comorbidity is Associated with Disease Activity in MS
Neurol 95:e446-e456, Salter, A.,et al, 2020
Radiologically Isolated Syndrome: A Review for Neuroradiologists
AJNR 41:1542-1549, Hosseiny, M.,et al, 2020
Paramagnetic Rim Lesions are Specific to Multiple Sclerosis:An International Multicenter 3T MRI Study
Ann Neurol 88:1034-1042, Maggi,P.,et al, 2020
Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis
JAMA Neurol 76:1446-1456, Sinnecker, T.,et al, 2019
Diet Quality is Associated with Disability and Symptom Severity in Multiple Sclerosis
Neurol 90:e1-e11, Fitzgerald, K.C.,et al, 2018
Evaluation of Idiopathic Transverse Myelitis Revealing Specific Myelopathy Diagnoses
Neurol 90:e96-102, Zalewski, N.L.,et al, 2018
Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018
Value of the Central Vein Sign at 3T to Differentiate MS from Seropositive NMOSD
Neurol 90:e1183-e1190, Cortese, R.,et al, 2018
Progressive multifocal leukoencephalpathy after fingolimod treatment
Neurol 90:1815-e1821, Berger, J.R.,et al, 2018
Prodromal Symptoms of Multiple Sclerosis in Primary Care
Ann Neurol 83:1162-1173, Disanto,G.,et al, 2018